Dinutuximab con chemioterapia, chirurgia e trapianto di cellule staminali per il trattamento dei bambini con neuroblastoma ad alto rischio di nuova diagnosi
Uno studio di fase 3 su dinutuximab aggiunto alla terapia multimodale intensiva per bambini con neuroblastoma ad alto rischio di nuova diagnosi
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
- Droga: Carboplatin
- Droga: Cyclophosphamide
- Droga: Cisplatin
- Procedura: Bone Marrow Biopsy
- Droga: Doxorubicin
- Droga: Vincristine
- Procedura: Magnetic Resonance Imaging
- Procedura: Echocardiography Test
- Procedura: Multigated Acquisition Scan
- Procedura: Bone Marrow Aspiration
- Droga: Etoposide
- Procedura: Computed Tomography
- Droga: Topotecan
- Radiazione: Radiation Therapy
- Procedura: Biospecimen Collection
- Altro: Survey Administration
- Droga: Melphalan
- Droga: Irinotecan
- Droga: Thiotepa
- Biologico: Dinutuximab
- Procedura: FDG-Positron Emission Tomography and Computed Tomography Scan
- Procedura: Hematopoietic Cell Transplantation
- Droga: Isotretinoin
- Procedura: Leukapheresis
- Procedura: Radionuclide Imaging
- Droga: Temozolomide
- Procedura: Tumor Resection
Descrizione dettagliata
PRIMARY OBJECTIVE:
I. To determine if the event-free survival (EFS) of patients with newly diagnosed high-risk neuroblastoma assigned to early chemoimmunotherapy during Induction differs from that of patients who are not assigned to treatment that includes early chemoimmunotherapy.
SECONDARY OBJECTIVES:
I. To determine if early chemoimmunotherapy during Induction therapy improves end of Induction (EOI) response rates and overall survival (OS) for patients with newly diagnosed high-risk neuroblastoma.
II. To determine response rates, EFS, and OS following an Extended Induction regimen with chemoimmunotherapy in patients with progressive disease or a poor response to Induction therapy.
III. To compare the toxicities experienced by patients treated with chemoimmunotherapy during Induction versus those experienced by patients treated with standard Induction and to describe toxicities experienced during Extended Induction.
IV. To determine GD2 expression on tumor tissue and tumor cells in bone marrow and assess for associations with response and outcome.
EXPLORATORY OBJECTIVES:
I. To describe the association between tumor and host factors and outcomes in patients receiving protocol therapy.
II. To evaluate circulating biomarkers and markers of minimal residual disease at baseline and during therapy, and assess for associations with response and outcome.
III. To compare patterns of failure between patients treated with and without dinutuximab during induction.
IV. To determine the effect of telomere maintenance mechanisms on end of Induction response rates, EFS, and OS.
V. To explore the impact of high-risk neuroblastoma (HRNBL) and its therapy, including the addition of dinutuximab to Induction chemotherapy, on functional and quality of life outcomes in patients with HRNBL, as measured by caregiver (parent/legal guardian) and patient questionnaires.
VI. To describe the adequacy of diagnostic biopsy specimens, including those obtained by percutaneous core needle biopsy.
VII. To explore the associations between family-reported adverse social determinants of health and both clinical outcomes and biology.
VIII. To develop and validate deep learning predictors of Induction response based on diagnostic MIBG scans. (Imaging Objective) IX. To compare institutional versus central determination of overall response, individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease), and poor end of induction response (PEIR) and good end of induction response (GEIR) determination. (Imaging Objective) X. To describe late toxicities (including impaired organ function, neuropsychiatric toxicity, and incidence of secondary malignancy) in patients treated with dinutuximab during Induction or Extended Induction to late toxicities in patients who have not received dinutuximab during these phases of therapy.
XI. To evaluate whether reduced dose radiotherapy to the primary site clinical target volume (CTV) in patients with complete response of the primary site at EOI results in comparable local control relative to historical cohorts.
XII. To compare post-transplant complications between treatment arms, and assess for associations with outcome.
XIII. To assess for associations between EOI response (including good end of Induction response [GEIR] and poor end of Induction response [PEIR]) and individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease) with outcome (EFS and OS).
XIV. To describe and compare the changes in image-defined risk factors (IDRFs) between patients treated with and without dinutuximab during Induction and associate with surgical outcomes and local failure rates following primary tumor resection.
XV. To bank serial samples of blood, bone marrow, and tumor tissue for future research.
OUTLINE: Patients receive Induction cycle 1 and are then randomized to 1 of 2 treatment arms.
INDUCTION CYCLE 1: Patients receive cyclophosphamide intravenously (IV) over 30 minutes and topotecan IV over 30 minutes on days 1-5 in the absence of unacceptable toxicity.
ARM A:
INDUCTION CYCLES 2-5: Patients receive cyclophosphamide IV over 30 minutes and topotecan IV over 30 minutes on days 1-5 of cycle 2 in the absence of unacceptable toxicity. Patients then undergo stem cell harvest via apheresis. Patients then receive cisplatin IV over 4 hours and etoposide IV over 2 hours on days 1-3 of cycles 3 and 5, and vincristine IV on day 1, doxorubicin IV over 15 minutes, and cyclophosphamide IV over 1 hour on days 1-2 of cycle 4 in the absence of unacceptable toxicity. Patients undergo primary tumor resection after Induction cycle 4 or 5. Following Induction cycle 5, patients undergo testing to determine response to Induction therapy. Patients with a good tumor response proceed to Consolidation, while patients with a poor tumor response proceed to Extended Induction.
EXTENDED INDUCTION: Patients with a poor tumor response or progression during Induction receive temozolomide orally (PO), via nasogastric tube (NG), or via gastric tube (G-tube) on days 1-5, irinotecan IV over 90 minutes on days 1-5, and dinutuximab IV over 10 hours. Treatment repeats every 21 days for up to a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity. If at any time during Extended Induction testing shows a good tumor response, patients proceed to Consolidation. If after 6 cycles of Extended Induction or if at any time progression is noted, patients are removed from the study.
CONSOLIDATION: Patients undergo two autologous hematopoietic stem cell transplantations (HSCTs) during Consolidation. Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 1 hour on days -5 to -2 during HSCT 1. Patients then receive stem cell infusion IV on day 0. Between 6 and 10 weeks after stem cell infusion, patients receive melphalan IV over 30 minutes on days -7 to -5, etoposide IV over 24 hours on days -7 to -4, and carboplatin over 24 hours on days -7 to -4 during HSCT 2. Patients receive stem cell infusion IV on day 0. Between day +42 and day +80 after HSCT 2. Patients receive radiation daily for 12 treatments in the absence of disease progression or unacceptable toxicity.
POST CONSOLIDATION: Patients receive dinutuximab IV over 10 hours on days 4-7 and isotretinoin PO twice daily (BID) on days 11-24 of cycles 1-5. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive isotretinoin PO BID on days 15-28 for 1 additional cycle, cycle 6.
Patients undergo blood and urine sample collection, echocardiogram (ECHO) or multigated acquisition scan (MUGA), bone marrow aspiration and/or biopsy, computed tomography (CT) scan, magnetic resonance imaging (MRI), iodine-123 meta-iodobenzylguanidine (I-MIBG) scan and possible fluorodeoxyglucose position emission tomography (FDG-PET) scan throughout the study.
ARM B:
INDUCTION CYCLES 2-5: Patients receive cyclophosphamide IV over 30 minutes, topotecan IV over 30 minutes on days 1-5, and dinutuximab IV over 10 hours on days 2-5 of cycle 2 in the absence of unacceptable toxicity. Patients then undergo stem cell harvest via apheresis. Patients receive cisplatin IV over 4 hours and etoposide IV over 2 hours on days 1-3 and dinutuximab IV over 10 hours on days 2-5 of cycles 3 and 5, and vincristine IV on day 1, doxorubicin IV over 15 minutes, and cyclophosphamide IV over 1 hour on days 1-2, and dinutuximab IV over 10 hours on days 2-5 of cycle 4 in the absence of unacceptable toxicity. Patients undergo primary tumor resection after Induction cycle 4 or 5. Following Induction cycle 5, patients undergo testing to determine response to Induction therapy. Patients with a good tumor response proceed to Consolidation, while patients with a poor tumor response proceed to Extended Induction.
EXTENDED INDUCTION: Patients with a poor tumor response or progression during Induction receive temozolomide PO, via NG tube, or via G-tube on days 1-5, irinotecan IV over 90 minutes on days 1-5, and dinutuximab IV over 10 hours. Treatment repeats every 21 days for up to a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity. If at any time during Extended Induction testing shows a good tumor response, patients proceed to Consolidation. If after 6 cycles of Extended Induction or if at any time progression is noted, patients are removed from the study.
CONSOLIDATION: Patients undergo two autologous HSCTs during Consolidation. Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 1 hour on days -5 to -2 during HSCT 1. Patients then receive stem cell infusion IV on day 0. Between 6 and 10 weeks after stem cell infusion patients receive melphalan IV over 30 minutes on days -7 to -5, etoposide IV over 24 hours on days -7 to -4, and carboplatin over 24 hours on days -7 to -4 during HSCT 2. Patients receive stem cell infusion IV on day 0. Between day +42 and day +80 after HSCT 2, patients receive radiation daily for 12 treatments in the absence of disease progression or unacceptable toxicity.
POST CONSOLIDATION: Patients receive dinutuximab IV over 10 hours on days 4-7 and isotretinoin PO BID on days 11-24 of cycles 1-5. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive isotretinoin PO BID on days 15-28 for 1 additional cycle, cycle 6.
Patients undergo blood and urine sample collection, ECHO or MUGA, bone marrow aspiration and/or biopsy, CT scan, MRI, I-MIBG scan and possible FDG-PET scan throughout the study.
After completion of study treatment, patients are followed up at 3, 6, 9,12, 15, 18, 24, 30, 36, 42, 48, 54, and 60 months and then periodically for up to 10 years from enrollment.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
New South Wales
-
Randwick, New South Wales, Australia, 2031
- Reclutamento
- Sydney Children's Hospital
-
Investigatore principale:
- Draga Barbaric
-
Contatto:
- Site Public Contact
- Numero di telefono: (02) 9382-1721
-
Westmead, New South Wales, Australia, 2145
- Reclutamento
- The Children's Hospital at Westmead
-
Contatto:
- Site Public Contact
- Numero di telefono: 61-2-9845 1400
-
Investigatore principale:
- Bhavna Padhye
-
-
Queensland
-
South Brisbane, Queensland, Australia, 4101
- Reclutamento
- Queensland Children's Hospital
-
Investigatore principale:
- Steven A. Foresto
-
Contatto:
- Site Public Contact
- Numero di telefono: 61 7 3068 1111
-
-
Victoria
-
Parkville, Victoria, Australia, 3052
- Reclutamento
- Royal Children's Hospital
-
Investigatore principale:
- Martin A. Campbell
-
Contatto:
- Site Public Contact
- Numero di telefono: 61 3 9345 5656
- Email: Jordan.Hansford@rch.org.au
-
-
Western Australia
-
Perth, Western Australia, Australia, 6009
- Reclutamento
- Perth Children's Hospital
-
Contatto:
- Site Public Contact
- Email: helpdesk@childrensoncologygroup.org
-
Investigatore principale:
- Michelle Ng
-
-
-
-
-
Québec, Canada, G1V 4G2
- Reclutamento
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
Investigatore principale:
- Bruno Michon
-
Contatto:
- Site Public Contact
- Numero di telefono: 418-525-4444
- Email: rechclinique@crchudequebec.ulaval.ca
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 6A8
- Reclutamento
- Alberta Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 403-220-6898
- Email: research4kids@ucalgary.ca
-
Investigatore principale:
- Victor A. Lewis
-
Edmonton, Alberta, Canada, T6G 2B7
- Reclutamento
- University of Alberta Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 780-407-8798
- Email: pedsoncologyresearch@ahs.ca
-
Investigatore principale:
- Sarah J. McKillop
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- Reclutamento
- British Columbia Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 6477 604-875-2345
-
Investigatore principale:
- Rebecca J. Deyell
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- Reclutamento
- CancerCare Manitoba
-
Contatto:
- Site Public Contact
- Numero di telefono: 866-561-1026
- Email: ctu_web@cancercare.mb.ca
-
Investigatore principale:
- Stephanie M. Villeneuve
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
- Reclutamento
- Janeway Child Health Centre
-
Investigatore principale:
- Lisa A. Goodyear
-
Contatto:
- Site Public Contact
- Numero di telefono: 709-777-8727
- Email: beverlyj.mitchell@easternhealth.ca
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3K 6R8
- Reclutamento
- IWK Health Centre
-
Contatto:
- Site Public Contact
- Numero di telefono: 902-470-8520
- Email: Research@iwk.nshealth.ca
-
Investigatore principale:
- Chelsea Ash
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- Reclutamento
- McMaster Children's Hospital at Hamilton Health Sciences
-
Contatto:
- Site Public Contact
- Numero di telefono: 905-521-2100
-
Investigatore principale:
- Uma H. Athale
-
London, Ontario, Canada, N6A 5W9
- Reclutamento
- Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 519-685-8306
-
Investigatore principale:
- Shayna M. Zelcer
-
Ottawa, Ontario, Canada, K1H 8L1
- Reclutamento
- Children's Hospital of Eastern Ontario
-
Contatto:
- Site Public Contact
- Numero di telefono: 613-737-7600
-
Investigatore principale:
- Donna L. Johnston
-
Toronto, Ontario, Canada, M5G 1X8
- Reclutamento
- Hospital for Sick Children
-
Contatto:
- Site Public Contact
- Numero di telefono: 416-813-7654
- Email: ask.CRS@sickkids.ca
-
Investigatore principale:
- Daniel A. Morgenstern
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 1P3
- Reclutamento
- The Montreal Children's Hospital of the MUHC
-
Contatto:
- Site Public Contact
- Numero di telefono: 514-412-4445
- Email: info@thechildren.com
-
Investigatore principale:
- Stephanie Mourad
-
Montreal, Quebec, Canada, H3T 1C5
- Reclutamento
- Centre Hospitalier Universitaire Sainte-Justine
-
Investigatore principale:
- Monia Marzouki
-
Contatto:
- Site Public Contact
- Numero di telefono: 514-345-4931
- Email: yvan.samson@umontreal.ca
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Reclutamento
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
Contatto:
- Site Public Contact
- Numero di telefono: 819-820-6480
- Email: crcinformation.chus@ssss.gouv.qc.ca
-
Investigatore principale:
- Stephanie Vairy
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N 0W8
- Reclutamento
- Jim Pattison Children's Hospital
-
Investigatore principale:
- Kathleen Felton
-
Contatto:
- Site Public Contact
- Numero di telefono: 306-655-3544
- Email: Jessica.Marien@saskhealthauthority.ca
-
-
-
-
Auckland
-
Grafton, Auckland, Nuova Zelanda, 1145
- Reclutamento
- Starship Children's Hospital
-
Investigatore principale:
- Andrew C. Wood
-
Contatto:
- Site Public Contact
- Numero di telefono: 0800 728 436
-
-
-
-
-
San Juan, Porto Rico, 00926
- Reclutamento
- University Pediatric Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 787-474-0333
-
Investigatore principale:
- Maria E. Echevarria
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35233
- Reclutamento
- Children's Hospital of Alabama
-
Contatto:
- Site Public Contact
- Numero di telefono: 205-638-9285
- Email: oncologyresearch@peds.uab.edu
-
Investigatore principale:
- Elizabeth D. Alva
-
Mobile, Alabama, Stati Uniti, 36604
- Reclutamento
- USA Health Strada Patient Care Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-388-8721
-
Investigatore principale:
- Hamayun Imran
-
-
Arizona
-
Mesa, Arizona, Stati Uniti, 85202
- Reclutamento
- Banner Children's at Desert
-
Contatto:
- Site Public Contact
- Numero di telefono: 480-412-3100
-
Investigatore principale:
- Joseph C. Torkildson
-
Phoenix, Arizona, Stati Uniti, 85016
- Reclutamento
- Phoenix Childrens Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 602-546-0920
-
Investigatore principale:
- Alok K. Kothari
-
Tucson, Arizona, Stati Uniti, 85719
- Reclutamento
- Banner University Medical Center - Tucson
-
Contatto:
- Site Public Contact
- Email: UACC-IIT@uacc.arizona.edu
-
Investigatore principale:
- Monica M. Davini
-
-
Arkansas
-
Little Rock, Arkansas, Stati Uniti, 72202-3591
- Reclutamento
- Arkansas Children's Hospital
-
Investigatore principale:
- Michael W. Bishop
-
Contatto:
- Site Public Contact
- Numero di telefono: 501-364-7373
-
-
California
-
Downey, California, Stati Uniti, 90242
- Reclutamento
- Kaiser Permanente Downey Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 626-564-3455
-
Investigatore principale:
- Robert M. Cooper
-
Duarte, California, Stati Uniti, 91010
- Reclutamento
- City of Hope Comprehensive Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-826-4673
- Email: becomingapatient@coh.org
-
Investigatore principale:
- Hung C. Tran
-
Loma Linda, California, Stati Uniti, 92354
- Reclutamento
- Loma Linda University Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 909-558-4050
-
Investigatore principale:
- Albert Kheradpour
-
Long Beach, California, Stati Uniti, 90806
- Reclutamento
- Miller Children's and Women's Hospital Long Beach
-
Contatto:
- Site Public Contact
- Numero di telefono: 562-933-5600
-
Investigatore principale:
- Jacqueline N. Casillas
-
Los Angeles, California, Stati Uniti, 90027
- Reclutamento
- Children's Hospital Los Angeles
-
Contatto:
- Site Public Contact
- Numero di telefono: 323-361-4110
-
Investigatore principale:
- Araz Marachelian
-
Los Angeles, California, Stati Uniti, 90048
- Reclutamento
- Cedars-Sinai Medical Center
-
Investigatore principale:
- Fataneh (Fae) Majlessipour
-
Contatto:
- Site Public Contact
- Numero di telefono: 310-423-2133
- Email: Cancer.trial.info@cshs.org
-
Los Angeles, California, Stati Uniti, 90095
- Reclutamento
- Mattel Children's Hospital UCLA
-
Contatto:
- Site Public Contact
- Numero di telefono: 310-825-6708
-
Investigatore principale:
- Satiro N. De Oliveira
-
Madera, California, Stati Uniti, 93636
- Reclutamento
- Valley Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 559-353-3000
- Email: Research@valleychildrens.org
-
Investigatore principale:
- Ruetima Titapiwatanakun
-
Oakland, California, Stati Uniti, 94611
- Reclutamento
- Kaiser Permanente-Oakland
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-642-4691
- Email: Kpoct@kp.org
-
Investigatore principale:
- Aarati V. Rao
-
Oakland, California, Stati Uniti, 94609
- Reclutamento
- UCSF Benioff Children's Hospital Oakland
-
Investigatore principale:
- Jennifer G. Michlitsch
-
Contatto:
- Site Public Contact
- Numero di telefono: 510-428-3264
- Email: PedOncRschOAK@ucsf.edu
-
Orange, California, Stati Uniti, 92868
- Reclutamento
- Children's Hospital of Orange County
-
Contatto:
- Site Public Contact
- Numero di telefono: 714-509-8646
- Email: oncresearch@choc.org
-
Investigatore principale:
- Elyssa M. Rubin
-
Palo Alto, California, Stati Uniti, 94304
- Reclutamento
- Lucile Packard Children's Hospital Stanford University
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-694-0012
- Email: ccto-office@stanford.edu
-
Investigatore principale:
- Jay Michael S. Balagtas
-
Sacramento, California, Stati Uniti, 95817
- Reclutamento
- University of California Davis Comprehensive Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 916-734-3089
-
Investigatore principale:
- Marcio H. Malogolowkin
-
Sacramento, California, Stati Uniti, 95816
- Reclutamento
- Sutter Medical Center Sacramento
-
Contatto:
- Site Public Contact
- Email: clinicalresearch@sutterhealth.org
-
Investigatore principale:
- Sandra Baril
-
San Diego, California, Stati Uniti, 92123
- Reclutamento
- Rady Children's Hospital - San Diego
-
Contatto:
- Site Public Contact
- Numero di telefono: 858-966-5934
-
Investigatore principale:
- William D. Roberts
-
San Francisco, California, Stati Uniti, 94158
- Reclutamento
- UCSF Medical Center-Mission Bay
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-827-3222
- Email: cancertrials@ucsf.edu
-
Investigatore principale:
- Arun A. Rangaswami
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- Reclutamento
- Children's Hospital Colorado
-
Investigatore principale:
- Navin R. Pinto
-
Contatto:
- Site Public Contact
- Numero di telefono: 303-764-5056
- Email: josh.b.gordon@nsmtp.kp.org
-
-
Connecticut
-
Hartford, Connecticut, Stati Uniti, 06106
- Reclutamento
- Connecticut Children's Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 860-545-9981
-
Investigatore principale:
- Michael S. Isakoff
-
New Haven, Connecticut, Stati Uniti, 06520
- Reclutamento
- Yale University
-
Contatto:
- Site Public Contact
- Numero di telefono: 203-785-5702
- Email: canceranswers@yale.edu
-
Investigatore principale:
- Farzana Pashankar
-
-
Delaware
-
Wilmington, Delaware, Stati Uniti, 19803
- Reclutamento
- Alfred I duPont Hospital for Children
-
Contatto:
- Site Public Contact
- Numero di telefono: 302-651-5572
- Email: Allison.bruce@nemours.org
-
Investigatore principale:
- Sridhi Patel
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stati Uniti, 20010
- Reclutamento
- Children's National Medical Center
-
Investigatore principale:
- Jeffrey S. Dome
-
Contatto:
- Site Public Contact
- Numero di telefono: 202-476-2800
- Email: OncCRC_OnCall@childrensnational.org
-
-
Florida
-
Fort Lauderdale, Florida, Stati Uniti, 33316
- Reclutamento
- Broward Health Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 302-651-5572
- Email: Allison.bruce@nemours.org
-
Investigatore principale:
- Hector M. Rodriguez-Cortes
-
Fort Myers, Florida, Stati Uniti, 33908
- Reclutamento
- Golisano Children's Hospital of Southwest Florida
-
Contatto:
- Site Public Contact
- Numero di telefono: 239-343-5333
- Email: molly.arnstrom@leehealth.org
-
Investigatore principale:
- Emad K. Salman
-
Gainesville, Florida, Stati Uniti, 32610
- Reclutamento
- UF Health Cancer Institute - Gainesville
-
Contatto:
- Site Public Contact
- Numero di telefono: 352-273-8010
- Email: cancer-center@ufl.edu
-
Investigatore principale:
- Brian Stover
-
Hollywood, Florida, Stati Uniti, 33021
- Reclutamento
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 954-265-1847
- Email: OHR@mhs.net
-
Investigatore principale:
- Iftikhar Hanif
-
Jacksonville, Florida, Stati Uniti, 32207
- Reclutamento
- Nemours Children's Clinic-Jacksonville
-
Contatto:
- Site Public Contact
- Numero di telefono: 302-651-5572
- Email: Allison.bruce@nemours.org
-
Investigatore principale:
- Sridhi Patel
-
Miami, Florida, Stati Uniti, 33155
- Reclutamento
- Nicklaus Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 888-624-2778
-
Investigatore principale:
- Ziad A. Khatib
-
Miami, Florida, Stati Uniti, 33136
- Reclutamento
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 305-243-2647
-
Investigatore principale:
- Meghan McCormick
-
Orlando, Florida, Stati Uniti, 32806
- Reclutamento
- Arnold Palmer Hospital for Children
-
Contatto:
- Site Public Contact
- Numero di telefono: 321-841-5357
- Email: Jennifer.spinelli@orlandohealth.com
-
Investigatore principale:
- Zhongbo Hu
-
Orlando, Florida, Stati Uniti, 32827
- Reclutamento
- Nemours Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 302-651-5572
- Email: Allison.bruce@nemours.org
-
Investigatore principale:
- Sridhi Patel
-
Orlando, Florida, Stati Uniti, 32803
- Reclutamento
- AdventHealth Orlando
-
Contatto:
- Site Public Contact
- Numero di telefono: 407-303-2090
- Email: FH.Cancer.Research@flhosp.org
-
Investigatore principale:
- Fouad M. Hajjar
-
St. Petersburg, Florida, Stati Uniti, 33701
- Reclutamento
- Johns Hopkins All Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 727-767-4784
- Email: Ashley.Repp@jhmi.edu
-
Investigatore principale:
- Jennifer B. Dean
-
West Palm Beach, Florida, Stati Uniti, 33407
- Reclutamento
- Saint Mary's Medical Center
-
Investigatore principale:
- Matthew D. Ramirez
-
Contatto:
- Site Public Contact
- Numero di telefono: 561-822-4745
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30329
- Reclutamento
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Investigatore principale:
- William T. Cash
-
Contatto:
- Site Public Contact
- Numero di telefono: 404-785-0232
- Email: Olivia.Floyd@choa.org
-
Savannah, Georgia, Stati Uniti, 31404
- Reclutamento
- Memorial Health University Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 912-350-7887
- Email: Lorraine.OHara@hcahealthcare.com
-
Investigatore principale:
- James N. Yarnall
-
-
Hawaii
-
Honolulu, Hawaii, Stati Uniti, 96826
- Reclutamento
- Kapiolani Medical Center for Women and Children
-
Contatto:
- Site Public Contact
- Numero di telefono: 808-983-6090
-
Investigatore principale:
- Wade T. Kyono
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Reclutamento
- Lurie Children's Hospital-Chicago
-
Contatto:
- Site Public Contact
- Numero di telefono: 773-880-4562
-
Investigatore principale:
- Elizabeth A. Sokol
-
Chicago, Illinois, Stati Uniti, 60637
- Reclutamento
- University of Chicago Comprehensive Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 773-702-8222
- Email: cancerclinicaltrials@bsd.uchicago.edu
-
Investigatore principale:
- Ami V. Desai
-
Chicago, Illinois, Stati Uniti, 60612
- Reclutamento
- University of Illinois
-
Contatto:
- Site Public Contact
- Numero di telefono: 312-355-3046
-
Investigatore principale:
- Dipti S. Dighe
-
Oak Lawn, Illinois, Stati Uniti, 60453
- Reclutamento
- Advocate Children's Hospital-Oak Lawn
-
Contatto:
- Site Public Contact
- Numero di telefono: 847-723-7570
-
Investigatore principale:
- Rebecca E. McFall
-
Park Ridge, Illinois, Stati Uniti, 60068
- Reclutamento
- Advocate Children's Hospital-Park Ridge
-
Contatto:
- Site Public Contact
- Email: helpdesk@childrensoncologygroup.org
-
Investigatore principale:
- Rebecca E. McFall
-
Peoria, Illinois, Stati Uniti, 61637
- Reclutamento
- OSF Children's Hospital of Illinois
-
Investigatore principale:
- Prerna Kumar
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-624-4945
- Email: ChildrensHospitalofIllinois@osfhealthcare.org
-
Springfield, Illinois, Stati Uniti, 62702
- Reclutamento
- Southern Illinois University School of Medicine
-
Contatto:
- Site Public Contact
- Numero di telefono: 217-545-7929
-
Investigatore principale:
- Gregory P. Brandt
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46202
- Reclutamento
- Riley Hospital for Children
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-248-1199
-
Investigatore principale:
- Marissa Just
-
Indianapolis, Indiana, Stati Uniti, 46260
- Reclutamento
- Ascension Saint Vincent Indianapolis Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 317-338-2194
- Email: research@stvincent.org
-
Investigatore principale:
- Bassem I. Razzouk
-
-
Iowa
-
Des Moines, Iowa, Stati Uniti, 50309
- Reclutamento
- Blank Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 515-241-8912
- Email: samantha.mallory@unitypoint.org
-
Investigatore principale:
- Samantha L. Mallory
-
Iowa City, Iowa, Stati Uniti, 52242
- Reclutamento
- University of Iowa/Holden Comprehensive Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-237-1225
-
Investigatore principale:
- Andrew P. Groves
-
-
Kansas
-
Wichita, Kansas, Stati Uniti, 67214
- Reclutamento
- Wesley Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 316-962-7802
- Email: WesleyResearch@wesleymc.com
-
Investigatore principale:
- Nathan S. Hall
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti, 40536
- Reclutamento
- University of Kentucky/Markey Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 859-257-3379
-
Investigatore principale:
- James T. Badgett
-
Louisville, Kentucky, Stati Uniti, 40202
- Reclutamento
- Norton Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 502-629-5500
- Email: CancerResource@nortonhealthcare.org
-
Investigatore principale:
- Michael J. Ferguson
-
-
Louisiana
-
New Orleans, Louisiana, Stati Uniti, 70118
- Reclutamento
- Children's Hospital New Orleans
-
Investigatore principale:
- Maria C. Velez-Yanguas
-
Contatto:
- Site Public Contact
- Numero di telefono: 504-894-5377
-
-
Maine
-
Bangor, Maine, Stati Uniti, 04401
- Reclutamento
- Eastern Maine Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 207-973-4274
-
Investigatore principale:
- Daniel L. Callaway
-
Scarborough, Maine, Stati Uniti, 04074
- Reclutamento
- Maine Children's Cancer Program
-
Investigatore principale:
- Sei-Gyung K. Sze
-
Contatto:
- Site Public Contact
- Numero di telefono: 207-396-8670
- Email: clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- Reclutamento
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Investigatore principale:
- Allen R. Chen
-
Contatto:
- Site Public Contact
- Numero di telefono: 410-955-8804
- Email: jhcccro@jhmi.edu
-
Baltimore, Maryland, Stati Uniti, 21215
- Reclutamento
- Sinai Hospital of Baltimore
-
Investigatore principale:
- Jason M. Fixler
-
Contatto:
- Site Public Contact
- Numero di telefono: 410-601-9083
-
Baltimore, Maryland, Stati Uniti, 21201
- Reclutamento
- University of Maryland/Greenebaum Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-888-8823
-
Investigatore principale:
- Teresa A. York
-
Bethesda, Maryland, Stati Uniti, 20889-5600
- Reclutamento
- Walter Reed National Military Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 301-319-2100
-
Investigatore principale:
- Kip R. Hartman
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114
- Reclutamento
- Massachusetts General Hospital Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-726-5130
-
Investigatore principale:
- Lauren H. Boal
-
Boston, Massachusetts, Stati Uniti, 02215
- Reclutamento
- Dana-Farber Cancer Institute
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-442-3324
-
Investigatore principale:
- Suzanne Shusterman
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109
- Reclutamento
- C S Mott Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-865-1125
-
Investigatore principale:
- Rajen Mody
-
Detroit, Michigan, Stati Uniti, 48201
- Sospeso
- Children's Hospital of Michigan
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Reclutamento
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 616-391-1230
- Email: crcwm-regulatory@crcwm.org
-
Investigatore principale:
- Kathleen Y. Butler
-
Kalamazoo, Michigan, Stati Uniti, 49007
- Reclutamento
- Bronson Methodist Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 616-391-1230
- Email: crcwm-regulatory@crcwm.org
-
Investigatore principale:
- Kathleen Y. Butler
-
Royal Oak, Michigan, Stati Uniti, 48073
- Reclutamento
- Corewell Health Children's
-
Contatto:
- Site Public Contact
- Numero di telefono: 248-551-7695
-
Investigatore principale:
- Marie V. Nelson
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55404
- Reclutamento
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Investigatore principale:
- Michael K. Richards
-
Contatto:
- Site Public Contact
- Numero di telefono: 612-813-5913
- Email: pauline.mitby@childrensmn.org
-
Minneapolis, Minnesota, Stati Uniti, 55455
- Reclutamento
- University of Minnesota/Masonic Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 612-624-2620
-
Investigatore principale:
- Robin L. Williams
-
Rochester, Minnesota, Stati Uniti, 55905
- Reclutamento
- Mayo Clinic in Rochester
-
Contatto:
- Site Public Contact
- Numero di telefono: 855-776-0015
-
Investigatore principale:
- Peter Schoettler
-
-
Mississippi
-
Jackson, Mississippi, Stati Uniti, 39216
- Reclutamento
- University of Mississippi Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 601-815-6700
-
Investigatore principale:
- Amanda Strobel
-
-
Missouri
-
Columbia, Missouri, Stati Uniti, 65212
- Reclutamento
- University of Missouri Children's Hospital
-
Investigatore principale:
- Barbara A. Gruner
-
Contatto:
- Site Public Contact
- Numero di telefono: 573-882-1960
- Email: snwq62@health.missouri.edu
-
Kansas City, Missouri, Stati Uniti, 64108
- Reclutamento
- Children's Mercy Hospitals and Clinics
-
Investigatore principale:
- Keith J. August
-
Contatto:
- Site Public Contact
- Numero di telefono: 816-302-6808
- Email: COGResearchGroup@cmh.edu
-
St Louis, Missouri, Stati Uniti, 63110
- Reclutamento
- Washington University School of Medicine
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-600-3606
- Email: info@siteman.wustl.edu
-
Investigatore principale:
- Frederick S. Huang
-
St Louis, Missouri, Stati Uniti, 63141
- Reclutamento
- Mercy Hospital Saint Louis
-
Contatto:
- Site Public Contact
- Numero di telefono: 314-251-7066
-
Investigatore principale:
- Robin D. Hanson
-
-
Nebraska
-
Omaha, Nebraska, Stati Uniti, 68114
- Reclutamento
- Children's Hospital and Medical Center of Omaha
-
Contatto:
- Site Public Contact
- Numero di telefono: 402-955-3949
-
Investigatore principale:
- Jill C. Beck
-
Omaha, Nebraska, Stati Uniti, 68198
- Reclutamento
- University of Nebraska Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 402-559-6941
- Email: unmcrsa@unmc.edu
-
Investigatore principale:
- Jill C. Beck
-
-
Nevada
-
Las Vegas, Nevada, Stati Uniti, 89135
- Reclutamento
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Contatto:
- Site Public Contact
- Numero di telefono: 702-384-0013
- Email: research@sncrf.org
-
Investigatore principale:
- Joseph L. Lasky
-
-
New Hampshire
-
Lebanon, New Hampshire, Stati Uniti, 03756
- Reclutamento
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Investigatore principale:
- Angela Ricci
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-639-6918
- Email: cancer.research.nurse@dartmouth.edu
-
-
New Jersey
-
Hackensack, New Jersey, Stati Uniti, 07601
- Reclutamento
- Hackensack University Medical Center
-
Investigatore principale:
- Katharine Offer
-
Contatto:
- Site Public Contact
- Numero di telefono: 551-996-2897
-
Morristown, New Jersey, Stati Uniti, 07960
- Reclutamento
- Morristown Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 973-971-5900
-
Investigatore principale:
- Kathryn L. Laurie
-
New Brunswick, New Jersey, Stati Uniti, 08901
- Reclutamento
- Saint Peter's University Hospital
-
Investigatore principale:
- Nibal A. Zaghloul
-
Contatto:
- Site Public Contact
- Numero di telefono: 732-745-8600
- Email: officeofresearch@saintpetersuh.com
-
New Brunswick, New Jersey, Stati Uniti, 08903
- Reclutamento
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 732-235-8675
-
Investigatore principale:
- Nehal S. Parikh
-
Newark, New Jersey, Stati Uniti, 07112
- Reclutamento
- Newark Beth Israel Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 973-926-7230
- Email: Christine.Kosmides@rwjbh.org
-
Investigatore principale:
- Teena Bhatla
-
Paterson, New Jersey, Stati Uniti, 07503
- Reclutamento
- Saint Joseph's Regional Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 973-754-2207
- Email: HallL@sjhmc.org
-
Investigatore principale:
- Alissa Kahn
-
-
New Mexico
-
Albuquerque, New Mexico, Stati Uniti, 87106
- Sospeso
- University of New Mexico Cancer Center
-
-
New York
-
Albany, New York, Stati Uniti, 12208
- Reclutamento
- Albany Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 518-262-5513
-
Investigatore principale:
- Lauren R. Weintraub
-
Buffalo, New York, Stati Uniti, 14263
- Reclutamento
- Roswell Park Cancer Institute
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-767-9355
- Email: askroswell@roswellpark.org
-
Investigatore principale:
- Clare J. Twist
-
Mineola, New York, Stati Uniti, 11501
- Reclutamento
- NYU Langone Hospital - Long Island
-
Contatto:
- Site Public Contact
- Numero di telefono: 212-263-4432
- Email: cancertrials@nyulangone.org
-
Investigatore principale:
- Chana L. Glasser
-
New Hyde Park, New York, Stati Uniti, 11040
- Reclutamento
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
Contatto:
- Site Public Contact
- Numero di telefono: 718-470-3460
-
Investigatore principale:
- Julie I. Krystal
-
New York, New York, Stati Uniti, 10032
- Reclutamento
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
Investigatore principale:
- Nobuko Hijiya
-
Contatto:
- Site Public Contact
- Numero di telefono: 212-342-5162
- Email: cancerclinicaltrials@cumc.columbia.edu
-
New York, New York, Stati Uniti, 10016
- Reclutamento
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Investigatore principale:
- Elizabeth A. Raetz
-
Contatto:
- Site Public Contact
- Email: CancerTrials@nyulangone.org
-
Rochester, New York, Stati Uniti, 14642
- Reclutamento
- University of Rochester
-
Contatto:
- Site Public Contact
- Numero di telefono: 585-275-5830
-
Investigatore principale:
- Rafi R. Kazi
-
Syracuse, New York, Stati Uniti, 13210
- Reclutamento
- State University of New York Upstate Medical University
-
Contatto:
- Site Public Contact
- Numero di telefono: 315-464-5476
-
Investigatore principale:
- Melanie A. Comito
-
The Bronx, New York, Stati Uniti, 10467
- Reclutamento
- Montefiore Medical Center - Moses Campus
-
Contatto:
- Site Public Contact
- Numero di telefono: 718-379-6866
- Email: eskwak@montefiore.org
-
Investigatore principale:
- Alice Lee
-
Valhalla, New York, Stati Uniti, 10595
- Reclutamento
- New York Medical College
-
Contatto:
- Site Public Contact
- Numero di telefono: 914-594-3794
-
Investigatore principale:
- Andrew J. Bellantoni
-
-
North Carolina
-
Asheville, North Carolina, Stati Uniti, 28801
- Reclutamento
- Mission Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 828-213-7055
- Email: NCDV.ResearchRegulatory@HCAHealthcare.com
-
Investigatore principale:
- Douglas J. Scothorn
-
Chapel Hill, North Carolina, Stati Uniti, 27599
- Reclutamento
- UNC Lineberger Comprehensive Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-668-0683
- Email: cancerclinicaltrials@med.unc.edu
-
Investigatore principale:
- Thomas B. Alexander
-
Charlotte, North Carolina, Stati Uniti, 28203
- Reclutamento
- Carolinas Medical Center/Levine Cancer Institute
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-804-9376
-
Investigatore principale:
- Joel A. Kaplan
-
Charlotte, North Carolina, Stati Uniti, 28204
- Reclutamento
- Novant Health Presbyterian Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 980-201-6360
- Email: kashah@novanthealth.org
-
Investigatore principale:
- Holly Edington
-
Durham, North Carolina, Stati Uniti, 27710
- Reclutamento
- Duke University Medical Center
-
Investigatore principale:
- Jessica M. Sun
-
Contatto:
- Site Public Contact
- Numero di telefono: 888-275-3853
-
Greenville, North Carolina, Stati Uniti, 27834
- Reclutamento
- East Carolina University
-
Contatto:
- Site Public Contact
- Numero di telefono: 252-744-1015
- Email: eubankss@ecu.edu
-
Investigatore principale:
- Andrea R. Whitfield
-
Winston-Salem, North Carolina, Stati Uniti, 27157
- Reclutamento
- Wake Forest University Health Sciences
-
Contatto:
- Site Public Contact
- Numero di telefono: 336-713-6771
-
Investigatore principale:
- Sarah Supples
-
-
North Dakota
-
Fargo, North Dakota, Stati Uniti, 58122
- Reclutamento
- Sanford Broadway Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 701-323-5760
- Email: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Investigatore principale:
- Samuel J. Milanovich
-
-
Ohio
-
Akron, Ohio, Stati Uniti, 44308
- Reclutamento
- Children's Hospital Medical Center of Akron
-
Contatto:
- Site Public Contact
- Numero di telefono: 330-543-3193
-
Investigatore principale:
- Lauren R. Draper
-
Cincinnati, Ohio, Stati Uniti, 45229
- Reclutamento
- Cincinnati Children's Hospital Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 513-636-2799
- Email: cancer@cchmc.org
-
Investigatore principale:
- Katherine M. Somers
-
Cleveland, Ohio, Stati Uniti, 44195
- Reclutamento
- Cleveland Clinic Foundation
-
Contatto:
- Site Public Contact
- Numero di telefono: 866-223-8100
- Email: TaussigResearch@ccf.org
-
Investigatore principale:
- Matteo M. Trucco
-
Cleveland, Ohio, Stati Uniti, 44106
- Reclutamento
- Rainbow Babies and Childrens Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 216-844-5437
-
Investigatore principale:
- Duncan S. Stearns
-
Columbus, Ohio, Stati Uniti, 43205
- Reclutamento
- Nationwide Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 614-722-6039
- Email: Melinda.Triplet@nationwidechildrens.org
-
Investigatore principale:
- Mark A. Ranalli
-
Dayton, Ohio, Stati Uniti, 45404
- Reclutamento
- Dayton Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-228-4055
-
Investigatore principale:
- Jordan M. Wright
-
Toledo, Ohio, Stati Uniti, 43606
- Reclutamento
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 419-824-1842
- Email: PCIOncResearch@promedica.org
-
Investigatore principale:
- Jamie L. Dargart
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- Reclutamento
- University of Oklahoma Health Sciences Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 405-271-8777
- Email: ou-clinical-trials@ouhsc.edu
-
Investigatore principale:
- Rene Y. McNall-Knapp
-
Tulsa, Oklahoma, Stati Uniti, 74136
- Reclutamento
- Saint Francis Children's Hospital
-
Investigatore principale:
- Jill A. Salo
-
Contatto:
- Site Public Contact
- Numero di telefono: 918-502-6720
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97227
- Reclutamento
- Legacy Emanuel Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 503-413-2560
-
Investigatore principale:
- Jason M. Glover
-
Portland, Oregon, Stati Uniti, 97239
- Reclutamento
- Oregon Health and Science University
-
Contatto:
- Site Public Contact
- Numero di telefono: 503-494-1080
- Email: trials@ohsu.edu
-
Investigatore principale:
- Susan J. Lindemulder
-
-
Pennsylvania
-
Allentown, Pennsylvania, Stati Uniti, 18103
- Reclutamento
- Lehigh Valley Hospital-Cedar Crest
-
Contatto:
- Site Public Contact
- Numero di telefono: 610-402-9543
- Email: Morgan_M.Horton@lvhn.org
-
Investigatore principale:
- Jacob A. Troutman
-
Danville, Pennsylvania, Stati Uniti, 17822
- Reclutamento
- Geisinger Medical Center
-
Investigatore principale:
- Jagadeesh Ramdas
-
Contatto:
- Site Public Contact
- Numero di telefono: 570-271-5251
- Email: cancerresearch@geisinger.edu
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Reclutamento
- Children's Hospital of Philadelphia
-
Investigatore principale:
- Rochelle Bagatell
-
Contatto:
- Site Public Contact
- Numero di telefono: 267-425-5544
- Email: CancerTrials@email.chop.edu
-
Philadelphia, Pennsylvania, Stati Uniti, 19134
- Reclutamento
- Saint Christopher's Hospital for Children
-
Contatto:
- Site Public Contact
- Numero di telefono: 215-427-8991
-
Investigatore principale:
- Gregory E. Halligan
-
Pittsburgh, Pennsylvania, Stati Uniti, 15224
- Reclutamento
- Children's Hospital of Pittsburgh of UPMC
-
Contatto:
- Site Public Contact
- Numero di telefono: 412-692-8570
- Email: jean.tersak@chp.edu
-
Investigatore principale:
- Jean M. Tersak
-
-
Rhode Island
-
Providence, Rhode Island, Stati Uniti, 02903
- Reclutamento
- Rhode Island Hospital
-
Investigatore principale:
- Bradley DeNardo
-
Contatto:
- Site Public Contact
- Numero di telefono: 401-444-1488
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29425
- Reclutamento
- Medical University of South Carolina
-
Contatto:
- Site Public Contact
- Numero di telefono: 843-792-9321
- Email: hcc-clinical-trials@musc.edu
-
Investigatore principale:
- Jacqueline M. Kraveka
-
Columbia, South Carolina, Stati Uniti, 29203
- Reclutamento
- Prisma Health Richland Hospital
-
Investigatore principale:
- Stuart L. Cramer
-
Contatto:
- Site Public Contact
- Numero di telefono: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Stati Uniti, 29605
- Reclutamento
- BI-LO Charities Children's Cancer Center
-
Investigatore principale:
- Aniket Saha
-
Contatto:
- Site Public Contact
- Numero di telefono: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Stati Uniti, 57117-5134
- Reclutamento
- Sanford USD Medical Center - Sioux Falls
-
Contatto:
- Site Public Contact
- Numero di telefono: 605-312-3320
- Email: OncologyClinicalTrialsSF@SanfordHealth.org
-
Investigatore principale:
- Jordan Fritch-Hanson
-
-
Tennessee
-
Knoxville, Tennessee, Stati Uniti, 37916
- Reclutamento
- East Tennessee Childrens Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 865-541-8266
-
Investigatore principale:
- Susan E. Spiller
-
Memphis, Tennessee, Stati Uniti, 38105
- Reclutamento
- Saint Jude Children's Research Hospital
-
Investigatore principale:
- Sara M. Federico
-
Contatto:
- Site Public Contact
- Numero di telefono: 888-226-4343
- Email: referralinfo@stjude.org
-
Nashville, Tennessee, Stati Uniti, 37232
- Reclutamento
- Vanderbilt University/Ingram Cancer Center
-
Investigatore principale:
- Daniel J. Benedetti
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-811-8480
-
Nashville, Tennessee, Stati Uniti, 37203
- Reclutamento
- The Children's Hospital at TriStar Centennial
-
Contatto:
- Site Public Contact
- Numero di telefono: 615-342-1919
-
Investigatore principale:
- Clinton M. Carroll
-
-
Texas
-
Austin, Texas, Stati Uniti, 78723
- Reclutamento
- Dell Children's Medical Center of Central Texas
-
Contatto:
- Site Public Contact
- Numero di telefono: 512-628-1902
- Email: TXAUS-DL-SFCHemonc.research@ascension.org
-
Investigatore principale:
- Shannon M. Cohn
-
Corpus Christi, Texas, Stati Uniti, 78411
- Reclutamento
- Driscoll Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 361-694-5311
- Email: Crystal.DeLosSantos@dchstx.org
-
Investigatore principale:
- Nkechi I. Mba
-
Dallas, Texas, Stati Uniti, 75390
- Reclutamento
- UT Southwestern/Simmons Cancer Center-Dallas
-
Investigatore principale:
- Tanya C. Watt
-
Contatto:
- Site Public Contact
- Numero di telefono: 214-648-7097
- Email: canceranswerline@UTSouthwestern.edu
-
Dallas, Texas, Stati Uniti, 75230
- Reclutamento
- Medical City Dallas Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 972-566-5588
-
Investigatore principale:
- Maurizio L. Ghisoli
-
El Paso, Texas, Stati Uniti, 79905
- Reclutamento
- El Paso Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 915-298-5444
- Email: ranjan.bista@ttuhsc.edu
-
Investigatore principale:
- Benjamin Carcamo
-
Fort Worth, Texas, Stati Uniti, 76104
- Reclutamento
- Cook Children's Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 682-885-2103
- Email: CookChildrensResearch@cookchildrens.org
-
Investigatore principale:
- Chelsee Greer
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 713-798-1354
- Email: burton@bcm.edu
-
Investigatore principale:
- Jennifer H. Foster
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- UT MD Anderson Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 866-632-6789
- Email: askmdanderson@mdanderson.org
-
Investigatore principale:
- Najat C. Daw
-
Lubbock, Texas, Stati Uniti, 79410
- Reclutamento
- Covenant Children's Hospital
-
Investigatore principale:
- Kishor M. Bhende
-
Contatto:
- Site Public Contact
- Numero di telefono: 806-725-8657
- Email: mbisbee@providence.org
-
Lubbock, Texas, Stati Uniti, 79415
- Reclutamento
- UMC Cancer Center / UMC Health System
-
Contatto:
- Site Public Contact
- Numero di telefono: 806-775-8590
-
Investigatore principale:
- Erin K. Barr
-
San Antonio, Texas, Stati Uniti, 78207
- Reclutamento
- Children's Hospital of San Antonio
-
Contatto:
- Site Public Contact
- Numero di telefono: 210-704-2894
- Email: bridget.medina@christushealth.org
-
Investigatore principale:
- Julie Voeller
-
San Antonio, Texas, Stati Uniti, 78229
- Reclutamento
- University of Texas Health Science Center at San Antonio
-
Contatto:
- Site Public Contact
- Numero di telefono: 210-450-3800
- Email: phoresearchoffice@uthscsa.edu
-
Investigatore principale:
- Aaron J. Sugalski
-
San Antonio, Texas, Stati Uniti, 78229
- Reclutamento
- Methodist Children's Hospital of South Texas
-
Contatto:
- Site Public Contact
- Numero di telefono: 210-575-6240
- Email: Vinod.GidvaniDiaz@hcahealthcare.com
-
Investigatore principale:
- Jose M. Esquilin
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84113
- Reclutamento
- Primary Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 801-585-5270
-
Investigatore principale:
- Leonora R. Slatnick
-
-
Vermont
-
Burlington, Vermont, Stati Uniti, 05405
- Reclutamento
- University of Vermont and State Agricultural College
-
Contatto:
- Site Public Contact
- Numero di telefono: 802-656-8990
- Email: rpo@uvm.edu
-
Investigatore principale:
- Jessica L. Heath
-
-
Virginia
-
Charlottesville, Virginia, Stati Uniti, 22908
- Reclutamento
- University of Virginia Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 434-243-6303
- Email: uvacancertrials@hscmail.mcc.virginia.edu
-
Investigatore principale:
- Brian C. Belyea
-
Portsmouth, Virginia, Stati Uniti, 23708-2197
- Reclutamento
- Naval Medical Center - Portsmouth
-
Contatto:
- Site Public Contact
- Numero di telefono: 757-953-5939
-
Investigatore principale:
- Karin Brockman
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98105
- Reclutamento
- Seattle Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 866-987-2000
-
Investigatore principale:
- Sarah E. Leary
-
Spokane, Washington, Stati Uniti, 99204
- Reclutamento
- Providence Sacred Heart Medical Center and Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-228-6618
- Email: HopeBeginsHere@providence.org
-
Investigatore principale:
- Judy L. Felgenhauer
-
Tacoma, Washington, Stati Uniti, 98405
- Reclutamento
- Mary Bridge Children's Hospital and Health Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 253-403-1461
- Email: research@multicare.org
-
Investigatore principale:
- Robert G. Irwin
-
-
West Virginia
-
Huntington, West Virginia, Stati Uniti, 25701
- Reclutamento
- Edwards Comprehensive Cancer Center
-
Investigatore principale:
- Mark A. Ranalli
-
Contatto:
- Site Public Contact
- Numero di telefono: 304-399-6566
- Email: Christina.Cole@chhi.org
-
Morgantown, West Virginia, Stati Uniti, 26506
- Reclutamento
- West Virginia University Healthcare
-
Contatto:
- Site Public Contact
- Numero di telefono: 304-293-7374
- Email: cancertrialsinfo@hsc.wvu.edu
-
Investigatore principale:
- Ashley E. Meyer
-
-
Wisconsin
-
Green Bay, Wisconsin, Stati Uniti, 54301
- Sospeso
- Saint Vincent Hospital Cancer Center Green Bay
-
Madison, Wisconsin, Stati Uniti, 53792
- Reclutamento
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-622-8922
- Email: clinicaltrials@cancer.wisc.edu
-
Investigatore principale:
- Margo L. Hoover-Regan
-
Marshfield, Wisconsin, Stati Uniti, 54449
- Reclutamento
- Marshfield Medical Center-Marshfield
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Investigatore principale:
- Michelle A. Manalang
-
Milwaukee, Wisconsin, Stati Uniti, 53226
- Reclutamento
- Children's Hospital of Wisconsin
-
Investigatore principale:
- Angela Steineck
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-955-4727
- Email: MACCCTO@mcw.edu
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Patients must be enrolled on APEC14B1 and have consented to testing through the Molecular Characterization Initiative (MCI), prior to enrollment on ANBL2131
-
≤ 30 years at the time of initial diagnosis with high-risk disease
-
* Must have a diagnosis of neuroblastoma (NBL) or ganglioneuroblastoma (nodular) verified by tumor pathology analysis or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamines
-
Newly diagnosed, high risk neuroblastoma (HRNBL) defined as one of the following:
- Any age with International Neuroblastoma Risk Group (INRG) Stage L2, MS, or M and MYCN amplification
- Age ≥ 547 days and INRG stage M regardless of biologic features (clinical MYCN testing not required prior to enrollment)
- Any age initially diagnosed with INRG Stage L1 MYCN amplified NBL who have progressed to stage M without systemic chemotherapy
- Age ≥ 547 days of age initially diagnosed with INRG Stage L1, L2, or MS who have progressed to stage M without systemic chemotherapy (clinical MYCN testing not required prior to enrollment)
-
-
Patients must have a body surface area (BSA) ≥ 0.25 m^2
-
No prior anti-cancer therapy except as outlined below:
- Patients initially recognized to have high-risk disease treated with topotecan/cyclophosphamide initiated on an emergent basis and within allowed timing, and with consent
- Patients observed or treated with a single cycle of chemotherapy per a low or intermediate risk neuroblastoma regimen (e.g., as per ANBL0531, ANBL1232 or similar) for what initially appeared to be non-high-risk disease but subsequently found to meet the criteria
- Patients who received localized emergency radiation to sites of life threatening or function-threatening disease prior to or immediately after establishment of the definitive diagnosis
-
Human immunodeficiency virus (HIV) -infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
A serum creatinine based on age/sex as follows:
-
1 month to < 6 months: Male 0.4 mg/dL and female 0.4mg/dL
-
6 months to < 1 year: Male 0.5 mg/dL and female 0.5 mg/dL
-
1 to < 2 years: Male 0.6 mg/dL and female 0.6 mg/dL
-
2 to < 6 years: Male 0.8 mg/dL and female 0.8 mg/dL
-
6 to < 10 years: Male 1 mg/dL and female 1 mg/dL
-
10 to < 13 years: Male 1.2 mg/dL and female 1.2 mg/dL
-
13 to < 16 years: Male 1.5 mg/dL and female 1.4 mg/dL
-
≥ 16 years: Male 1.7 mg/dL and female 1.4 mg/dL
- The threshold creatinine values were derived from the Schwartz formula for estimating glomerular filtration rate (GFR) utilizing child length and stature data published by the Centers for Disease Control (CDC)
-
or a 24-hour urine creatinine clearance ≥ 70 mL/min/1.73 m^2 or
-
or a GFR ≥ 70 mL/min/1.73 m^2. GFR must be performed using direct measurement with a nuclear blood sampling method or direct small molecule clearance method (iothalamate or other molecule per institutional standard)
- Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibility
-
-
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age
-
Serum glutamic pyruvic transaminase (SGPT) (Alanine aminotransferase [ALT]) ≤ 10 x ULN*
- Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
-
* Shortening fraction of ≥ 27% by echocardiogram, or
- Ejection fraction of ≥ 50% by echocardiogram or radionuclide angiogram
-
Ability to tolerate Peripheral Blood Stem Cell (PBSC) collection:
No known contraindication to PBSC collection. Examples of contraindications might be a weight or size less than the collecting institution finds feasible, or a physical condition that would limit the ability of the child to undergo apheresis catheter placement (if necessary) and/or the apheresis procedure
Exclusion Criteria:
- Patients who are 365-546 days of age with INRG Stage M and MYCN non-amplified NBL, irrespective of additional biologic features
- Patients ≥ 547 days of age with INRG Stage L2, MYCN non-amplified NBL, regardless of additional biologic features
- Patients with known bone marrow failure syndromes
- Patients on chronic immunosuppressive medications (e.g., tacrolimus, cyclosporine, corticosteroids) for reasons other than prevention/treatment of allergic reactions and adrenal replacement therapy are not eligible. Topical and inhaled corticosteroids are acceptable
- Patients with a primary immunodeficiency syndrome who require ongoing immune globulin replacement therapy
- Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required prior to enrollment for female patients of childbearing potential
- Lactating females who plan to breastfeed their infants
- Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
- All patients and/or their parents or legal guardians must sign a written informed consent
- All institutional, food and drug administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Arm A (SOC treatment)
See detailed description |
Given IV
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo bone marrow biopsy
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo MRI
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo bone marrow aspiration Given IV
Altri nomi:
Undergo CT scan
Altri nomi:
Given IV
Altri nomi:
Undergo radiation therapy
Altri nomi:
Undergo blood and urine sample collection
Altri nomi:
Ancillary studies Given IV
Altri nomi:
Given IV Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo FDG PET
Altri nomi:
Undergo stem cell infusion
Altri nomi:
Given PO
Altri nomi:
Undergo apheresis
Altri nomi:
Undergo I-MIBG scan
Altri nomi:
Given PO or via NG or G tube
Altri nomi:
Undergo tumor resection surgery |
|
Sperimentale: Arm B (Dinutuximab in induction)
See detailed description |
Given IV
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo bone marrow biopsy
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo MRI
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo bone marrow aspiration Given IV
Altri nomi:
Undergo CT scan
Altri nomi:
Given IV
Altri nomi:
Undergo radiation therapy
Altri nomi:
Undergo blood and urine sample collection
Altri nomi:
Ancillary studies Given IV
Altri nomi:
Given IV Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo FDG PET
Altri nomi:
Undergo stem cell infusion
Altri nomi:
Given PO
Altri nomi:
Undergo apheresis
Altri nomi:
Undergo I-MIBG scan
Altri nomi:
Given PO or via NG or G tube
Altri nomi:
Undergo tumor resection surgery |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Event free survival (EFS)
Lasso di tempo: Up to 3 years
|
EFS time is calculated from time of randomization to Arms A or B to first episode of disease relapse or progression, second malignancy, or death, or until last contact if no event has occurred. |
Up to 3 years
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
End of Induction (EOI) response rate
Lasso di tempo: From randomization to end of extended Induction, up to 12 months
|
The response rate will be calculated among all evaluable patients at end of Induction. Responders are defined as patients who achieve a >= partial response per the revised 2017 International Neuroblastoma Response Criteria (INRC) |
From randomization to end of extended Induction, up to 12 months
|
|
Overall survival (OS)
Lasso di tempo: Up to 3 years
|
OS time is calculated from time of randomization to Arms A or B until death, or until last contact if patient is alive. |
Up to 3 years
|
|
Incidence of adverse events
Lasso di tempo: Up to 2 years
|
The proportion of patients with at least one grade 3 or higher non-hematologic toxicity or grade 4 or higher hematologic toxicity during protocol therapy, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, will be reported. |
Up to 2 years
|
|
GD2 expression
Lasso di tempo: Up to 12 months
|
Dinutuximab binding to pre-therapy patient tumor samples will be measured and categorized as high or low. |
Up to 12 months
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Association between tumor and host factors and outcomes
Lasso di tempo: Up to 10 years
|
A series of univariate and multivariate Cox proportional hazards (for EFS and OS) and logistic regression (for responders vs. non-responders) models will be fit for patients in Arms A and B to evaluate the relationship between tumor and host factors (including tumor ALK and other somatic mutations, copy-number aberrations, gene fusions, gene expression, and pathogenic germline variants) and chemo-immunotherapy during Induction with outcome. |
Up to 10 years
|
|
Circulating biomarkers and markers of minimal residual disease
Lasso di tempo: Up to 10 years
|
Will be assessed by comparing the proportion of patients with detectable vs. non-detectable tumor markers (including circulating tumor deoxyribonucleic acid, circulating free DNA, circulating tumor cells, and immune function profiling) between Arms A and B during and after induction and post-consolidation therapy using chi-squared tests at each individual time point, and Cochran's Q across time points to determine if there is a consistent difference in proportions between arms across time. In addition, the tumor markers will be analyzed as continuous variables using longitudinal data analysis methodology such as mixed effects models or generalized estimating equations as appropriate. |
Up to 10 years
|
|
Patterns of failure
Lasso di tempo: Up to 10 years
|
The impact of early or late chemoimmunotherapy during Induction on the probability of the involvement of a specific disease site at first relapse will be evaluated using Fisher's exact test. |
Up to 10 years
|
|
Effect of telomere maintenance mechanisms
Lasso di tempo: Up to 10 years
|
A series of univariate and multivariate Cox proportional hazards (for EFS and OS) and logistic regression (for responders vs. non-responders) models will be fit for patients in arms A and B to evaluate the relationship between telomere maintenance mechanism and chemoimmunotherapy during Induction with outcome. Patients will be classified into 3 groups by telomere maintenance mechanism (TMM) based on messenger ribonucleic acid expression of TERT and analysis of telomeric DNA C-circles: telomerase (TERT) positive, alternative of lengthening of telomeres (ALT) positive, or no identified TMM. |
Up to 10 years
|
|
Functional and quality of life outcomes
Lasso di tempo: At serial time points during Induction, Extended Induction, Post-Consolidation, and at the end of therapy
|
Will descriptively summarize and compare the total Memorial Symptom Assessment Scale scores, total sub-domain scores, and individual symptom scores between patients randomized to receive dinutuximab during Induction (Arm B) to those of patients randomized to standard Induction (Arm A). |
At serial time points during Induction, Extended Induction, Post-Consolidation, and at the end of therapy
|
|
Adequacy of diagnostic biopsy specimens
Lasso di tempo: At time of tissue collection
|
Will be evaluated by descriptively comparing the successful delineation of histologic classification, MYCN amplification status, and ALK status via the traditional method of obtaining tissue for diagnosis, open surgical biopsy, versus the less invasive percutaneous core needle biopsy. |
At time of tissue collection
|
|
Associations between family-reported adverse social determinants of health and both clinical outcomes and biology
Lasso di tempo: Up to 10 years
|
Kaplan-Meier curves of EFS and OS will be generated and used to calculate 3-year EFS and OS estimates. Associations between social determinants of health (SDOH) and survival outcomes and time to receipt of dinutuximab will be evaluated with univariate and multivariate Cox proportional hazard models. Log-binomial regression will be used to estimate risk ratios and 95% CI for the occurrence of dinutuximab consent to randomization and therapy receipt by SDOH exposure. Effect modification of outcomes as a function of poverty, stratified by race/ethnicity, will be explored. |
Up to 10 years
|
|
Develop and validate deep learning predictors of Induction response (imaging objective)
Lasso di tempo: At diagnosis, EOI, during Extended Induction, and end of Extended Induction
|
Scans will be given as input to a convolutional neural network trained to predict EOI response. |
At diagnosis, EOI, during Extended Induction, and end of Extended Induction
|
|
Compare institutional versus central determination of overall response, individual response components, and PEIR and GEIR determination (imaging objective)
Lasso di tempo: Up to 10 years
|
Will be assessed by calculating the percentage of patients receiving the same EOI institutional and centrally reviewed determination of overall response, individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease), and PEIR and GEIR. In addition, Cohen's kappa will be calculated to evaluate the concordance in each of these response measures. |
Up to 10 years
|
|
Incidence of late toxicities
Lasso di tempo: Up to 10 years
|
Will be addressed by calculating the proportion of treated patients with each late effect, including but not limited to impaired organ function, neuropsychiatric toxicity, and secondary malignancy. A 95% confidence interval will be placed on each proportion. |
Up to 10 years
|
|
Reduced dose radiotherapy to the primary site clinical target volume (CTV) in patients with complete response of the primary site at EOI results in comparable local control relative to historical cohorts
Lasso di tempo: Up to 10 years
|
The cumulative incidence of local progression (CILP) in patients with complete response of the primary site at EOI and GEIR on this study will be compared to the CILP rate of 11.2±1.8% observed on ANBL0532 using Gray's test. |
Up to 10 years
|
|
Post-transplant complications
Lasso di tempo: Up to 100 days post-transplant
|
Will be evaluated by calculating the incidence of endothelial injury complications and non-relapse mortality within 100 days of transplant, transplant-associated thrombotic microangiopathy (TA-TMA), severe TA-TMA, and sinusoidal obstruction syndrome (SOS) on Arms A and B and comparing between arms with a chi-squared test. The impact of TA-TMA occurrence on the timing or exclusion of subsequent therapy and interventions utilized to treat the TA-TMA, and associations with outcomes (EFS and OS) will be assessed. |
Up to 100 days post-transplant
|
|
Associations between end of induction (EOI) response and individual response components
Lasso di tempo: Up to 10 years
|
Log-rank tests will be used to explore the association between EOI response (using both the revised INRC and GEIR/PEIR classification) and individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease) with outcome (EFS and OS). |
Up to 10 years
|
|
Changes in image-defined risk factors (IDRF)
Lasso di tempo: Up to 10 years
|
The proportion of patients in the analytic cohort for whom each particular IDRF and also the presence of any IDRF is absent prior to surgical resection will be computed. McNemar's test for paired observations will be applied to determine whether there is a difference in the proportion of each IDRF and any IDRF present before and after initial therapy, and conditional logistic regression will be used to compare between treatment arms A and B. The IDRF status after initial therapy and whether there has been a change from diagnosis will be associated with surgical outcome (complete vs. incomplete resection, presence or absence of surgical complications) using chi-squared tests, and compared between treatment arms A and B with the Cochran-Mantel-Haenszel test. The association of IDRF status with presence or absence of local failure after primary tumor resection will also be evaluated using a chi-squared test, and compared between treatment arms A and B with the Cochran-Mantel-Haenszel. |
Up to 10 years
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Sara M Federico, Children's Oncology Group
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie
- Neoplasie per tipo istologico
- Neoplasie, ghiandolari ed epiteliali
- Neoplasie, Neuroepiteliali
- Tumori neuroectodermici
- Neoplasie, cellule germinali ed embrionali
- Neoplasie, tessuto nervoso
- Tumori neuroectodermici, primitivi, periferici
- Tumori neuroectodermici, primitivi
- Neuroblastoma
- Ganglioneuroblastoma
- Organizzazione e amministrazione
- Amministrazione dei servizi sanitari
- Aminoacidi, peptidi e proteine
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Tecniche investigative
- Terapie
- Tecniche di laboratorio clinico
- Tecniche e procedure diagnostiche
- Diagnosi
- Procedure chirurgiche, operative
- Azoli
- Tecniche citologiche
- Citodiagnosi
- Retinoidi
- Carotenoidi
- Polienni
- Alcheni
- Idrocarburi, aciclici
- Idrocarburi
- Ciclohexenes
- Ciclohexanes
- Cicloparaffins
- Idrocarburi, aliciclici
- Idrocarburi, ciclici
- Terpeni
- Pigmenti, biologici
- Fattori biologici
- Carboidrati
- Fenomeni fisici
- Camptothecin
- Alcaloidi
- Podofillotossina
- Tetraidonaftalene
- Naftalene
- Idrocarburi policiclici aromatici
- Idrocarburi, aromatici
- Composti policiclici
- Glucosidi
- Glicosidi
- Dacarbazine
- Triazenes
- Imidazoli
- Trapianto
- Indoli
- Prodotti chimici inorganici
- Composti di cloro
- Composti di azoto
- Complessi di coordinamento
- Aminoacidi
- Elementi
- Metalli
- Tecniche diagnostiche, chirurgiche
- Tecniche di chimica, analitiche
- Analisi dello spettro
- Senape di fosforamide
- Composti di senape di azoto
- Composti di senape
- Idrocarburi, alogenati
- Fosforamidi
- Composti organofosfori
- Metalli, pesante
- Vinca Alkaloids
- Alcaloidi di triptamina di secologia
- Alcaloidi indolo
- Indolizidine
- Indolizine
- Antracicline
- Naftaceni
- Aminoglicosidi
- Composti di platino
- Daunorubicina
- Elementi di transizione
- Trapianto di cellule
- Terapia a base di cellule e tessuti
- Terapia biologica
- Citaferesi
- Rimozione della componente del sangue
- Procedure di riduzione dei leucociti
- Separazione cellulare
- Fenilalanina
- Aminoacidi, aromatici
- Aminoacidi, ciclici
- Amministrazione ospedaliera
- Amministrazione delle strutture sanitarie
- Trietilenefosforamide
- Aziridine
- Azirines
- Procedure chirurgiche urologiche
- Procedure chirurgiche urogenitali
- Temozolomide
- Irinotecano
- Ciclofosfamide
- Melfalan
- Etoposide
- Carboplatino
- Doxorubicina
- Vincristina
- Cisplatino
- Isotretinoina
- Tiotepa
- Topotecan
- 1,2-diamminocicloesaneplatino II citrato
- Radioterapia
- Radiazione
- Biopsia
- Gestione dei campioni
- Spettroscopia di risonanza magnetica
- Platino
- Dinutuximab
- Trapianto di cellule staminali
- Trapianto di cellule staminali ematopoietiche
- Leukaferesi
- Dipartimento di medicina nucleare, ospedale
- Resezione transuretrale della vescica
Altri numeri di identificazione dello studio
- NCI-2023-08530
- U10CA180886 (Sovvenzione/contratto NIH degli Stati Uniti)
- NCI-2023-08530 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- ANBL2131 (Altro identificatore: CTEP)
- ANBL2131 (Altro identificatore: Children's Oncology Group)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page."
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .